schliessen

Filtern

 

Bibliotheken

1.

FDA Approval Summary: Sonidegib-Response
by Shord, Stacy S

Clinical cancer research : an official journal of the American Association for Cancer Research, 01 October 2017, Vol.23(19), pp.5994

2.

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
by Khozin, Sean

Clinical cancer research : an official journal of the American Association for Cancer Research, May 1, 2017, Vol.23(9), pp.2131-2135

3.

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma
by Casey, Denise

Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, May 15, 2017, Vol.23(10), pp.2377-2381

4.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
by Barone, Amy

Clinical cancer research : an official journal of the American Association for Cancer Research, October 1, 2017, Vol.23(19), pp.5661-5665

5.

FDA Approval Summary: TAS-102.
by Marcus, Leigh

Clinical cancer research : an official journal of the American Association for Cancer Research, June 15, 2017, Vol.23(12), pp.2924-2927

6.

FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
by Barone, Amy

Clinical cancer research : an official journal of the American Association for Cancer Research, December 15, 2017, Vol.23(24), pp.7448-7453

7.

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
by Chuk, Meredith K

Clinical cancer research : an official journal of the American Association for Cancer Research, October 1, 2017, Vol.23(19), pp.5666-5670

8.

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
by Hazarika, Maitreyee

Clinical cancer research : an official journal of the American Association for Cancer Research, 15 July 2017, Vol.23(14), pp.3484-3488

10.

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
by Lemery, Steven J

Clinical cancer research : an official journal of the American Association for Cancer Research, September 1, 2010, Vol.16(17), pp.4331-4338

11.

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
by Axelson, Michael

Clinical cancer research : an official journal of the American Association for Cancer Research, May 1, 2013, Vol.19(9), pp.2289-2293

13.

FDA Approval Summary: Ramucirumab for Gastric Cancer
by Casak, Sandra

Clinical Cancer Research, August 1, 2015, Vol.21(15), pp.3372-3376

14.

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.
by Khozin, Sean

Clinical cancer research : an official journal of the American Association for Cancer Research, June 1, 2015, Vol.21(11), pp.2436-2439

16.

Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
by Donoghue, Martha

Clinical cancer research : an official journal of the American Association for Cancer Research, March 15, 2012, Vol.18(6), pp.1496-1505

12

Recommended databases

Find more Articles matching your search terms in these recommended databases.

Filter electronic articles 25 Hits

Remove Filters